Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6340-6347

  Zhao, Min ^a,b,c   Bousquet, Elodie ^a,b,c   Valamanesh, Fatemeh ^a,b,c,d   Farman, Nicolette ^b   Jeanny, Jean Claude ^a,b,c   Jaisser, Frederic ^b   Behar Cohen, Francine F ^a,b,c,d,e  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^e HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR4.1; MESSENGER RNA; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; AQP4 PROTEIN, RAT; GLUCOCORTICOID; POTASSIUM INWARDLY RECTIFYING CHANNEL, SUBFAMILY J, MEMBER 10; POTASSIUM INWARDLY-RECTIFYING CHANNEL, SUBFAMILY J, MEMBER 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENDOTOXIN INDUCED UVEITIS; FEMALE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEITIS; VITREOUS BODY; WESTERN BLOTTING; ANIMAL; DOSE RESPONSE; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; INTRAVITREAL DRUG ADMINISTRATION; LEWIS RAT; METABOLISM; RETINA;

ANIMALS; AQUAPORIN 4; BLOTTING, WESTERN; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUCOCORTICOIDS; IMMUNOHISTOCHEMISTRY; INTRAVITREAL INJECTIONS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RATS; RATS, INBRED LEW; RETINA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAMCINOLONE ACETONIDE; UVEITIS;

EID: 80053484714     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7675     Document Type: Article

References (41)

1. Newman E, Reichenbach A. The Müller cell: a functional element of the retina. Trends Neurosci. 1996;19:307-312.
2. Reichenbach A, Stolzenburg JU, Eberhardt W, et al. What do retinal Muller (glial) cells do for their neuronal "small siblings"? J Chem Neuroanat. 1993;6:201-213.
3. Goodyear MJ, Crewther SG, Junghans BM. A role for aquaporin-4 in fluid regulation in the inner retina. Vis Neurosci. 2009;26:159-165.
4. Verkman AS, Ruiz-Ederra J, Levin MH. Functions of aquaporins in the eye. Prog Retin Eye Res. 2008;27:420-433.
5. Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and diseased retina. Prog Retin Eye Res. 2006;25:397-424.
6. Iandiev I, Wurm A, Hollborn M, et al. Muller cell response to blue light injury of the rat retina. Invest Ophthalmol Vis Sci. 2008;49: 3559-3567.
7. Ren H, Xu G, Qian J, et al. Muller cells upregulate the expression of SAP97 in light-injured rat retina. Neuroreport. 2010;21:832-836.
8. Rehak M, Hollborn M, Iandiev I, et al. Retinal gene expression and Muller cell responses after branch retinal vein occlusion in the rat. Invest Ophthalmol Vis Sci. 2009;50:2359-2367.
9. Liu XQ, Kobayashi H, Jin ZB, et al. Differential expression of Kir4.1 and aquaporin 4 in the retina from endotoxin-induced uveitis rat. Mol Vis. 2007;13:309-317.
10. Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Expert Opin Pharmacother. 2009;10:2511-2525.
11. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009;116:902-911.
12. Silva PS, Sun JK, Aiello LP. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24:93-99.
13. Gomez-Ulla F, Marticorena J, Alfaro DV 3rd, et al. Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr Diabetes Rev. 2006;2:99-112.
14. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503-522.
15. Aiello LP, Edwards AR, Beck RW, et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/ grid photocoagulation for diabetic macular edema. Ophthalmology. 2010;117:946-953.
16. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146e3.
17. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol. 2001;280:F181-F192.
18. Pippal JB, Fuller PJ. Structure-function relationships in the mineralocorticoid receptor. J Mol Endocrinol. 2008;41:405-413.
19. Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:Art. e012.
20. Revollo JR, Cidlowski JA. Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci. 2009;1179:167-178.
21. Zhao M, Valamanesh F, Celerier I, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Muller glial cells. FASEB J. 2010;24:3405-3415.
22. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-225.
23. Baath J, Ells AL, Crichton A, et al. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther. 2007;23:304-310.
24. Touchard E, Omri S, Naud MC, et al. A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2010;51:4683-4693.
25. Oakley RH, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissuespecific actions of glucocorticoids. J Biol Chem. 2011;286:3177-3184.
26. Valamanesh F, Torriglia A, Savoldelli M, et al. Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Mol Vis. 2007;13:1746-1757.
27. Bocchi B, Fagart J, Cluzeaud F, et al. Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity. J Steroid Biochem Mol Biol. 2003;84:239-244.
28. Rebuffat AG, Tam S, Nawrocki AR, et al. The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Mol Cell Endocrinol. 2004;214:27-37.
29. Grossmann C, Scholz T, Rochel M, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151:397-406.
30. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells (Abstract). BMC Med Genomics. 2009;2:58.
31. Hellal-Levy C, Couette B, Fagart J, et al. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 1999;464:9-13.
32. Fagart J, Couette B, Souque A, et al. Photoaffinity labelling of the human mineralocorticoid receptor with steroids having a reactive group at position 3, 18 or 21. Biochim Biophys Acta. 1998;1388: 35-44.
33. Sande PH, Fernandez DC, Aldana Marcos HJ, et al. Therapeutic effect of melatonin in experimental uveitis. Am J Pathol. 2008; 173:1702-1713.
34. Betancur C, Borrell J, Guaza C. Cytokine regulation of corticosteroid receptors in the rat hippocampus: effects of interleukin-1, interleukin-6, tumor necrosis factor and lipopolysaccharide. Neuroendocrinology. 1995;62:47-54.
35. Sierra A, Gottfried-Blackmore A, Milner TA, et al. Steroid hormone receptor expression and function in microglia. Glia. 2008;56:659-674.
36. Smith JR, Choi D, Chipps TJ, et al. Unique gene expression profiles of donor-matched human retinal and choroidal vascular endothelial cells. Invest Ophthalmol Vis Sci. 2007;48:2676-2684.
37. Dejager L, Pinheiro I, Puimege L, et al. Increased glucocorticoid receptor expression and activity mediate the LPS resistance of SPRET/EI mice. J Biol Chem. 2010;285:31073-31086.
38. Escoubet B, Coureau C, Blot-Chabaud M, et al. Corticosteroid receptor mRNA expression is unaffected by corticosteroids in rat kidney, heart, and colon. Am J Physiol Cell Physiol. 1996;270: C1343-C1353.
39. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300:7-16.
40. Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatr Nephrol. 2007;22:778-784.
41. Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291-1293.